First Patient Dosed in Ph 1 Combo Cohort of MEM-288 + Docetaxel in Advanced NSCLC
“Dosing the first patient in this combination cohort marks an important milestone for the MEM-288 program,” said Mark Cantwell, Ph.D., Chief Scientific Officer, Memgen. “Docetaxel remains a backbone in the second-line setting, yet outcomes are still disappointing, with median overall survival typically less than one year. Combining intratumoral MEM-288 with chemotherapy has strong biological rationale. Our goal with this study is to improve the depth and durability of response and, ultimately, deliver a clinically meaningful improvement over the current standard of care for patients facing significant unmet need.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib